The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule. They write that despite their concern over rising drug prices and high costs of cancer care, they do not support a mandatory, national experiment on patient care. They add that they have serious concerns about the impact of the model on the care received by patients with cancer, the impacticality of its design, and its legaltiy. Based on these concerns, COA urges CMS to not move foward with the proposal.
Read the full comment letter.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More